Trials / Completed
CompletedNCT01534715
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients With Relapsed or Refractory Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- ImmunoGen, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMGN529 |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2016-07-01
- Completion
- 2016-07-01
- First posted
- 2012-02-17
- Last updated
- 2017-12-29
Locations
7 sites across 2 countries: United States, Switzerland
Source: ClinicalTrials.gov record NCT01534715. Inclusion in this directory is not an endorsement.